Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

NL0015002SN0
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG000GTYWL7
QGEN
Qiagen NV
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Medical - Diagnostics & Research
NAME
Qiagen NV
ISIN
NL0015002SN0
TICKER
QGEN
MIC
XNYS
REUTERS
QGEN.N
BLOOMBERG
QGEN US
Fri, 18.09.2026       Qiagen NV
NL0015002SN0

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it will hold an Extraordinary General Meeting of Shareholders on November 6, 2026, at 2:00 p.m. CET. Shareholders will be asked to vote on the appointment of Jonathan M. Pratt to the QIAGEN Managing Board after he joined QIAGEN as Chief Executive Officer on September 1,...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Thu, 27.08.2026       Qiagen NV
NL0015002SN0

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the commercial launch of QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction. Building on the trusted QIAsymphony platform, with more than 3,300 cumulative placements worldwide, QIAsymphony Connect helps clinical laboratories standar...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Mon, 24.08.2026       Qiagen NV
NL0015002SN0

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Jonathan M. Pratt has been appointed Chief Executive Officer, effective September 1, 2026. He brings to QIAGEN more than 25 years of international leadership experience across life sciences, laboratory technologies and healthcare. Jon Pratt most recently served as Presi...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Mon, 24.08.2026       Qiagen NV
NL0015002SN0

Ad-hoc-Mitteilung gemäß Art. 17 der Marktmissbrauchsverordnung QIAGEN ernennt Jonathan M. Pratt zum Vorstandsvorsitzenden Venlo, Niederlande, 24. August 2026 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute die Ernennung von Jonathan M. Pratt zum Vorstandsvorsitzenden mit Wirkung zum 1. September 2026 bekannt gegeben. Er bring......
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Mon, 24.08.2026       Qiagen NV
NL0015002SN0

Ad hoc Announcement according to Art. 17 Market Abuse Regulation   QIAGEN appoints Jonathan M. Pratt as Chief Executive Officer Venlo, the Netherlands, August 24, 2026 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announces that Jonathan M. Pratt has been appointed Chief Executive Officer, effective September 1, 2026. He brings......
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Mon, 10.08.2026       Qiagen NV
NL0015002SN0

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx BCID GPF Plus AMR Panel, the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance. The clearance expands QIAGEN’s U.S. syndromic testing portfolio into bloodstream infection diagnost...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Wed, 05.08.2026       Qiagen NV
NL0015002SN0

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced results for Q2 2026, with net sales and adjusted diluted earnings per share exceeding the outlook while maintaining a high level of profitability. Net sales for Q2 2026 were unchanged at $535 million on a reported basis and at constant exchange rates (CER) compared to Q2 202...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Wed, 15.07.2026       Qiagen NV
NL0015002SN0

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today highlighted its portfolio of molecular testing solutions supporting the public health response to the growing number of cyclosporiasis cases reported across the United States. More than 1,600 U.S. cases of cyclosporiasis have been confirmed since May, along with another 7,000 potentia...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Wed, 15.07.2026       Qiagen NV
NL0015002SN0

QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the second quarter of 2026. Press release date / time: Wednesday, August 5 shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, August 6, at 15:30 Frankfurt time / 14:30 London ti...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Tue, 14.07.2026       Qiagen NV
NL0015002SN0

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel, establishing a comprehensive bloodstream infection testing offering on the QIAstat-Dx platform in Europe. The new QIAstat-Dx BCID GN Plus AMR Panel detects 13 gram-negative bacterial pathogen targets and...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Mon, 06.07.2026       Qiagen NV
NL0015002SN0

Das Instrument QIA NL0015002SN0 QIAGEN NV EO -,01 EQUITY wird ex Dividende/Zinsen gehandelt am 07.07.2026 The instrument QIA NL0015002SN0 QIAGEN NV EO -,01 EQUITY has its ex-dividend/interest day on 07.07.2026...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.07.2026       Qiagen NV
NL0015002SN0

Das Instrument QIA NL0015002SN0 QIAGEN NV EO -,01 EQUITY wird ex Dividende/Zinsen gehandelt am 07.07.2026 The instrument QIA NL0015002SN0 QIAGEN NV EO -,01 EQUITY has its ex-dividend/interest day on 07.07.2026...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Sun, 05.07.2026       Qiagen NV
NL0015002SN0

Das Instrument QIA NL0015002SN0 QIAGEN NV EO -,01 EQUITY wird cum Dividende/Zinsen gehandelt am 06.07.2026 und ex Dividende/Zinsen am 07.07.2026 The instrument QIA NL0015002SN0 QIAGEN NV EO -,01 EQUITY has its pre-dividend/interest day on 06.07.2026 and its ex-dividend/interest day on 07.07.2026...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Mon, 15.06.2026       Qiagen NV
NL0015002SN0

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to its QIAcuity digital PCR (dPCR) ecosystem, with a focus on expanding gene expression capabilities, broadening assay content and enhancing workflow standardization to support the growing adoption of dPCR across life sciences and biopharma applications. As res...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Thu, 04.06.2026       Qiagen NV
NL0015002SN0

NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Qiagen N.V. ("Qiagen" or the "Company") (NYSE: QGEN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Thu, 28.05.2026       Qiagen NV
NL0015002SN0

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the availability of two custom-designed research-use-only (RUO) digital PCR assays to support infectious disease research and surveillance efforts related to the Bundibugyo ebolavirus outbreak. The assays are designed for use with the QIAcuity digital PCR system and are inte...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Thu, 28.05.2026       Qiagen NV
NL0015002SN0

NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Qiagen N.V. ("Qiagen" or the "Company") (NYSE: QGEN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Thu, 21.05.2026       Qiagen NV
NL0015002SN0

NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Qiagen N.V. ("Qiagen" or the "Company") (NYSE: QGEN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Wed, 20.05.2026       Qiagen NV
NL0015002SN0

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the global launch of QIA Agent, an AI-powered digital assistant designed to simplify how researchers plan experiments, identify suitable products, access technical information and manage ordering support through a single conversational interface. “Researchers today are navig...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Wed, 20.05.2026       Qiagen NV
NL0015002SN0

Qiagen shares dropped more than 10% after the company slashed FY 2026 sales-growth guidance from "at least 5% CER" to just 1-2% CER -- erasing hundreds of millions in market capitalization in a single session. NEW YORK, May 20, 2026 /PRNewswire/ -- Shareholders of Qiagen N.V. (NASDAQ: QGEN) saw over 10% wiped from the stock's value after the comp...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Wed, 20.05.2026       Qiagen NV
NL0015002SN0

The law firm of Kirby McInerney LLP continues its investigation on behalf of Qiagen N.V. (“Qiagen” or the “Company”) (NYSE:QGEN) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Tue, 19.05.2026       Qiagen NV
NL0015002SN0

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced at the 2026 BIO-IT World Conference & Expo in Boston that the QIAGEN Digital Insights bioinformatics business and its curated knowledge bases and bioinformatics expertise will be integrating NVIDIA accelerated computing and the NVIDIA BioNeMo platform to help researchers use AI more...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Fri, 15.05.2026       Qiagen NV
NL0015002SN0

NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Qiagen N.V. ("Qiagen" or the "Company") (NYSE: QGEN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Wed, 13.05.2026       Qiagen NV
NL0015002SN0

Qiagen's forward-looking non-GAAP guidance lacked required GAAP reconciliations under SEC Regulation S-K Item 10(e) -- institutional investors who relied on these figures for portfolio allocation decisions may have been deprived of material information. NEW YORK, May 13, 2026 /PRNewswire/ -- Qiagen N.V. (NASDAQ: QGEN) shares dropped approximately...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Wed, 13.05.2026       Qiagen NV
NL0015002SN0

The law firm of Kirby McInerney LLP is investigating potential claims against Qiagen N.V. (“Qiagen” or the “Company”) (NYSE:QGEN). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION]...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Tue, 12.05.2026       Qiagen NV
NL0015002SN0

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced proposals for its 2026 Annual General Meeting, including plans to appoint co-founder and former Chief Executive Officer Dr. Metin Colpan as Honorary Chairman, the continued renewal of the Supervisory Board and increased returns to shareholders. The Annual General Meeting, to be h...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Mon, 11.05.2026       Qiagen NV
NL0015002SN0

New York, New York--(Newsfile Corp. - May 11, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Qiagen N.V. (NYSE: QGEN) ("Qiagen N.V.")  concerning potential violations of the federal securities laws.During the previous earnings call on February 5, 2026, CEO Thierry Bernard was confident: "Y...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Thu, 07.05.2026       Qiagen NV
NL0015002SN0

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to advance its QuantiFERON latent tuberculosis (TB) test with a new fully automated Sample to Insight workflow and a separate AI-enabled risk stratification tool for TB progression, building on growing adoption of Diasorin LIAISON detection systems and a new automation p...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Thu, 07.05.2026       Qiagen NV
NL0015002SN0

New York, New York--(Newsfile Corp. - May 6, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Qiagen N.V. ("Qiagen N.V.") (NYSE: QGEN) concerning potential violations of the federal securities laws.During the previous earnings call on February 5, 2026, CEO Thierry Bernard was confident: "You will see Quant...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Wed, 06.05.2026       Qiagen NV
NL0015002SN0

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today reports full results for the first quarter of 2026 in line with the preliminary announcement, showing QIAGEN continuing to deliver strong profitability as adjusted diluted earnings per share (EPS) achieved the outlook. Sales trends were mixed, as lower QuantiFERON sales and cautious U.S...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Wed, 06.05.2026       Qiagen NV
NL0015002SN0

Qiagen projected a low single digit rate first-quarter QuantiFERON growth rate on February 5, 2026. Actual Q1 2026 volumes showed a 5% decline NEW YORK, May 6, 2026 /PRNewswire/ -- Qiagen N.V. (NYSE: QGEN) shares fell more than 10.5% after the company disclosed QuantiFERON faltered on "significantly lower immigration testing demand." Shareholders...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Fri, 01.05.2026       Qiagen NV
NL0015002SN0

New York, New York--(Newsfile Corp. - April 30, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Qiagen N.V. ("Qiagen N.V.") (NYSE: QGEN) concerning potential violations of the federal securities laws.During the previous earnings call on February 5, 2026, CEO Thierry Bernard was confident: "You will see Qu...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Tue, 28.04.2026       Qiagen NV
NL0015002SN0

Resetting Stressed Market State for Product [NL0015002SN0], Instrument [NL0015002SN0]...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Tue, 28.04.2026       Qiagen NV
NL0015002SN0

Setting Stressed Market State for Product [NL0015002SN0], Instrument [NL0015002SN0]...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Mon, 27.04.2026       Qiagen NV
NL0015002SN0

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary results for the first quarter of 2026, continuing to deliver strong profitability as adjusted diluted earnings per share (EPS) achieved the outlook. Sales trends were mixed, as lower QuantiFERON sales and cautious U.S. Life Sciences customer demand offset solid gro...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Mon, 27.04.2026       Qiagen NV
NL0015002SN0

Ad-hoc-Mitteilung gemäß Art. 17 Marktmissbrauchsverordnung QIAGEN meldet vorläufige Ergebnisse für das erste Quartal 2026 mit bereinigtem Gewinn je Aktie im Rahmen der Erwartungen bei gemischten Umsatztrends; Jahresprognose 2026 mit geringerem erwarteten Nettoumsatzwachstum und niedrigerem bereinigten verwässerten Gewinn je Aktie aktualisiert Ven......
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Mon, 27.04.2026       Qiagen NV
NL0015002SN0

Ad hoc Announcement according to Art. 17 Market Abuse Regulation  QIAGEN announces preliminary Q1 2026 results that achieved adjusted EPS outlook with mixed sales trends; updates full-year 2026 outlook by reducing expected net sales growth and adjusted diluted EPS   Venlo, the Netherlands, April 27, 2026 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prim......
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Thu, 16.04.2026       Qiagen NV
NL0015002SN0

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it will showcase its oncology workflow applications at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, demonstrating how its portfolio connects sample preparation with multi-omics profiling and genomic data interpretation to support cancer...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Tue, 14.04.2026       Qiagen NV
NL0015002SN0

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its expansion into syndromic testing for bloodstream infections with the launch of the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel. The launch of this new QIAstat-Dx panel coincides with the ESCMID Global 2026 Congress in Munich (April 17–21), where QIAGEN will high...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Fri, 20.03.2026       Qiagen NV
NL0015002SN0

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN’s website here. QIAGEN will provide print...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Thu, 19.03.2026       Qiagen NV
NL0015002SN0

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced newly published clinical and health economic data supporting the use of its QuantiFERON-TB Gold Plus (QFT-Plus) blood test for detecting tuberculosis (TB) infection, particularly in immunocompromised and other high-risk populations. The announcement is being made in time for...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Tue, 10.03.2026       Qiagen NV
NL0015002SN0

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the use of all QIAstat-Dx® Gastrointestinal (GI) Panels on the QIAstat-Dx Rise automated syndromic testing system. With this milestone, laboratories can run both QIAstat-Dx Respiratory and QIAstat-Dx GI panels on Q...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Thu, 19.02.2026       Qiagen NV
NL0015002SN0

Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Wed, 04.02.2026       Qiagen NV
NL0015002SN0

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced results for the fourth quarter and full-year 2025. Net sales for Q4 2025 rose 4% to $540 million, with sales at constant exchange rates (CER) up 1% and exceeding the outlook for steady CER results compared to the year-ago period while overcoming macroeconomic challenges and...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Tue, 03.02.2026       Qiagen NV
NL0015002SN0

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the first public showcase of QIAsprint Connect at SLAS 2026 in Boston, marking QIAGEN’s entry into high-throughput benchtop automation for sample processing in research laboratories. QIAsprint Connect is designed to help labs process large batches of samples efficiently whil...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Mon, 26.01.2026       Qiagen NV
NL0015002SN0

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Mark Stevenson has been appointed as an independent member of the Supervisory Board as of January 23, 2026, and will stand for election at the next Annual General Meeting in June 2026. In addition, Prof. Dr. Ross Levine has stepped down from the Supervisory Board also on Jan...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Mon, 19.01.2026       Qiagen NV
NL0015002SN0

QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the fourth quarter of 2025. Press release date / time: Wednesday, February 4 shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, February 5, at 15:30 Frankfurt time / 14:30 Londo...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Mon, 12.01.2026       Qiagen NV
NL0015002SN0

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its 2026 priorities across its five growth pillars focused on advancing product commercialization, regulatory milestones and automation system innovations to support its goal for $2 billion of combined annual pillar sales in 2028. Following strong operational execution in 20...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Wed, 07.01.2026       Qiagen NV
NL0015002SN0

Das Instrument QIA NL0015002SN0 QIAGEN NV EO -,01 EQUITY hat seinen ersten Handelstag am 08.01.2026: CONTINUOUS AUCTION SPECIALIST, PAG PAG_EQU, SettlCurr EUR, CCP Y The instrument QIA NL0015002SN0 QIAGEN NV EO -,01 EQUITY has its first trading date on 08.01.2026: CONTINUOUS AUCTION SPECIALIST, PAG PAG_EQU, SettlCurr EUR, CCP Y...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink
Tue, 06.01.2026       Qiagen NV
NL0015002CX3

Das Instrument QIA NL0015002CX3 QIAGEN NV EO -,01 EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument QIA NL0015002CX3 QIAGEN NV EO -,01 EQUITY is traded cum capital adjustment on 07.01.2026 and ex capital adjustment on 08.01.2026...
Read more
Qiagen NV
Technical Analysis Termsheets Terminal
Permalink